For the quarter ending 2026-03-31, TGTX had $363,071K increase in cash & cash equivalents over the period. -$17,945K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 19,777 | 23,037 | 390,895 | 33,247 |
| Loss on extinguishment of debt | -9,153 | 0 | 0 | - |
| Stock-based compensation | 19,950 | 15,651 | 17,686 | 31,333 |
| Depreciation and amortization | 32 | 21 | 17 | 21 |
| Amortization of premium (discount) on investment securities | 367 | 383 | 786 | 2,619 |
| Amortization of debt issuance costs | 285 | 304 | 304 | 608 |
| Amortization of leasehold interest | 48 | 46 | 45 | 94 |
| Deferred income taxes | 3,864 | 18,627 | -366,627 | - |
| Noncash change in lease liability and right of use asset | 573 | 432 | 431 | 885 |
| Change in fair value of equity investments | 1,534 | -433 | 420 | -285 |
| Change in fair value of notes payable | -88 | 136 | -14 | -149 |
| Change in inventory reserve | - | 6,171 | - | - |
| Increase in inventory | 13,275 | -563 | -8,695 | 42,710 |
| Decrease (increase) in other current assets | -10,661 | 1,911 | 30,632 | 9,887 |
| Increase in accounts receivable | 86,418 | 40,244 | 33,868 | 102,331 |
| (decrease) increase in income taxes payable | -6,718 | - | - | - |
| Increase in accounts payable and accrued expenses | 34,016 | 2,008 | -17,280 | 71,150 |
| Decrease in lease liabilities | -424 | -519 | -519 | -1,061 |
| Decrease in other current liabilities | -1,617 | 266 | -277 | -2,370 |
| (decrease) increase in deferred revenue | -5,988 | -4,706 | 9,169 | 1,927 |
| Net cash used in operating activities | -17,894 | 19,660 | -23,153 | -21,279 |
| Proceeds from maturity of held-to-maturity securities | 11,250 | 30,000 | 77,750 | 129,750 |
| Investment in held-to-maturity securities | 21,063 | 45,571 | 31,307 | 145,359 |
| Purchases of equity investments | 0 | 0 | 0 | 1,250 |
| Purchases of property, plant and equipment | 51 | 67 | 80 | 67 |
| Net cash used in investing activities | -9,864 | -15,638 | 46,363 | -16,926 |
| Payment of loan payable | -255,000 | 0 | 0 | - |
| Issuance of common stock, net | - | 0 | - | - |
| Proceeds from exercise of options | 763 | 1,058 | 0 | 453 |
| Proceeds from debt financings, net of debt discount costs | 747,656 | 0 | 0 | - |
| Financing costs paid | 2,598 | 0 | 0 | - |
| Purchase of treasury stock | 99,992 | 0 | 78,242 | 12,998 |
| Net cash provided by (used in) financing activities | 390,829 | 1,058 | -78,242 | -12,545 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 363,071 | 5,080 | -55,032 | -50,750 |
| Cash, cash equivalents and restricted cash at beginning of period | 80,490 | 75,410 | 181,192 | - |
| Cash, cash equivalents and restricted cash at end of period | 443,561 | 80,490 | 75,410 | - |
TG THERAPEUTICS, INC. (TGTX)
TG THERAPEUTICS, INC. (TGTX)